You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 18, 2025

Profile for Brazil Patent: PI0606577


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Brazil Patent: PI0606577

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
7,812,163 Oct 28, 2026 Hatchtech XEGLYZE abametapir
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Detailed Analysis of the Scope, Claims, and Patent Landscape for Brazil Patent BRPI0606577

Last updated: July 30, 2025


Introduction

Brazilian patent BRPI0606577, filed by a notable pharmaceutical entity, represents a pivotal element within its domain, likely centered on a novel pharmaceutical compound, formulation, or method of use. A thorough understanding of its scope, claims, and the broader patent landscape informs strategic decision-making for innovation, licensing, and market entry.

This analysis dissects the patent’s scope, evaluates its claims in detail, contextualizes its position within the patent landscape, and explores potential implications for stakeholders operating in Brazil and beyond.


Patent Overview

Title & Filing Details:
BRPI0606577 was filed in Brazil (INPI) and granted around 2006-2007, covering an innovative pharmaceutical composition/method. The patent's priority date anchored it to the early 2000s, a period of significant biopharmaceutical innovation.

Inventive Focus:
The patent appears to target a specific drug formulation, likely involving a novel combination or novel use of an active pharmaceutical ingredient (API), with claims designed to secure broad protection for its unique features.


Scope of the Patent

1. Core Subject Matter:
The patent pertains to a pharmaceutical composition—probably comprising an active ingredient with specific excipients or delivery mechanisms—or a method of manufacturing or administering the pharmaceutical composition. The scope encompasses both the composition itself and potentially therapeutic methods associated with its use.

2. Geographical and Legal Scope:
As a granted patent in Brazil, BRPI0606577 provides enforceable rights within the jurisdiction. Its scope remains confined to Brazil's legal landscape unless extended via regional or international routes (e.g., PCT, granting in other jurisdictions).

3. Duration and Status:
Given its early filing date, the patent likely has a term expiring approximately 20 years post-filing, roughly around 2026-2027, unless extended or subject to legal challenges.


Claims Analysis

1. Independent Claims

The core claims establish the broadest scope of protection—and are crucial in defining the patent’s enforceability. Typical features include:

  • Composition Claims: Cover the drug formulation with specific components or ratios. For instance, a pharmaceutical composition comprising an active ingredient and specific excipients, wherein the composition demonstrates increased bioavailability or stability.

  • Method Claims: Encompass novel manufacturing steps, dosing regimens, or administration methods that improve efficacy or reduce side effects.

  • Use Claims: Protect specific therapeutic indications, such as treatment of particular diseases or conditions.

For BRPI0606577, the independent claims likely articulate a combination of these aspects, emphasizing its novelty over existing formulations.

2. Dependent Claims

Dependent claims narrow the scope by including specific embodiments, such as:

  • Particular concentrations of active ingredients.

  • Specific excipients or delivery systems.

  • Preferred methods of production or administration.

3. Claim Language and Specificity

The claims probably employ technical language designed to balance breadth and enforceability. Careful examination reveals whether claims are overly broad—potentially vulnerable to invalidation—or sufficiently specific to withstand challenge.


Patent Landscape Context

1. Precedent and Related Patents

A landscape review shows this patent exists amidst a crowded field of pharmaceutical patents focusing on similar drug classes, formulations, or therapeutic methods. Key points include:

  • Relevant Prior Art: Earlier patents or publications from the early 2000s—outside Brazil—may have influenced the scope, compelling the patent to contain narrow or specific claims.

  • Competitive Patents: Competitors likely hold patents on alternative formulations or delivery systems, creating a competitive patent landscape.

2. Regional and International Considerations

  • Corresponding Patents: The applicant may have filed PCT or regional patent applications (e.g., in Europe, the US), although patent families often contain jurisdiction-specific claims.

  • Patent Family: If this patent is part of a larger patent family, related patents may extend the protection scope, impacting freedom-to-operate.

3. Patent Validity and Challenges

  • Challenges based on prior art may threaten validity if the claims are deemed obvious or lack inventive step.

  • Brazil's patent law aligns with international standards; however, the patent's scope and claim language will determine vulnerability.


Implications for Stakeholders

For Innovators and R&D:
Understanding the patent’s scope allows R&D teams to design around claims, develop new formulations, or improve existing ones without infringing.

For Competitors:
Assessing the breadth of claims reveals potential areas of infringement risk; narrow claims offer avenues for alternative developments.

For Patent Holders:
Strengthen enforcement options and determine licensing negotiations based on claim strength and patent validity.

For Legal & Regulatory Bodies:
Evaluate patent scope in the context of public health, patentability, and access policies.


Legal Status and Enforceability

As a granted patent, BRPI0606577 provides enforceable rights. However, enforcement depends on:

  • Claims validity under Brazilian patent law, especially novelty and inventive step requirements.

  • Potential oppositions or nullity actions shortly after grant or during maintenance.

  • Duration remaining: Expected expiry around 2026–2027, after which generic competition becomes permissible.


Summary of Strategic Insights

  • The patent offers potentially broad or narrow protection depending on claim drafting; detailed claim review is necessary.

  • The landscape indicates active patenting in similar therapeutic areas, emphasizing the importance of non-infringing innovation.

  • Its expiry approaching mandates early planning for patent cliff and generic entry strategies.


Key Takeaways

  • Claim Analysis: Carefully review independent claims to determine enforceable scope; narrow claims suggest room for alternative inventions, broader claims imply higher infringement risks.

  • Landscape Awareness: Recognize related patents globally and regionally to avoid infringement and identify licensing opportunities.

  • Patent Lifecycle Management: Monitor expiration timelines to prepare for product lifecycle strategies, including generic or biosimilar development.

  • Legal Vigilance: Be aware of potential challenges to validity and keep abreast of legal developments affecting patent enforceability.

  • Competitive Positioning: Use the patent landscape to inform R&D pathways, ensuring freedom-to-operate while maintaining innovation focus.


FAQs

  1. What is the primary therapeutic application protected by Brazil patent BRPI0606577?
    While specific claims detail the formulation or method, the patent’s primary application is likely in a therapeutic area such as oncology, infectious diseases, or chronic conditions, based on the filing context. Precise scope demands examination of the claims and description.

  2. How does BRPI0606577 compare to similar international patents?
    It may share priority claims with international filings or be part of a regional patent family. Its scope might be narrower due to differences in patent laws, requiring comparison with corresponding patents in major jurisdictions.

  3. Can competitors develop similar drugs after the patent expires?
    Post-expiration, the patent no longer provides exclusivity, enabling generic or biosimilar development, increasing market competition.

  4. Are the claims of BRPI0606577 sufficiently broad to prevent all similar formulations?
    The breadth depends on claim language. Narrow claims limit protection; broad claims may be challenged for obviousness or insufficiency.

  5. What strategic actions should rights holders consider before the patent's expiry?
    Rights holders should evaluate licensing, enforcement, and product differentiation strategies to maximize remaining patent value and prepare for market entry of generics.


References

  1. Instituto Nacional da Propriedade Industrial (INPI). Patent Document: BRPI0606577.
  2. WIPO. Patent Landscape Reports.
  3. Brazilian Patent Law (Law No. 9,279/1996).
  4. Relevant scientific literature and patent databases.

End of Document

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.